The International Antiviral Society–USA commissions volunteer panels of experts to develop clinical practice recommendations and guidelines in areas of antiviral medicine that are confusing or controversial. Funding for the guidelines is provided by the IAS–USA; commercial support is not accepted. Expert panel members participate on a volunteer basis.
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Preexposure Prophylaxis for HIV Updated Recommendations From the 2024 International Antiviral Society–USA Panel
Landovitz RJ, Molina JM, Buchbinder SP, et al. Preexposure Prophylaxis for HIVUpdated Recommendations From the 2024 International Antiviral Society–USA Panel. JAMA. 2025;334;(7):638-639. doi:10.1001/jama.2025.11410
Following the US Food and Drug Administration approval of lenacapavir for HIV preexposure prophylaxis (PrEP) on June 18, 2025, and the release of new data on the use of tenofovir alafenamide/emtricitabine among cisgender women, the International Antiviral Society-USA (IAS-USA) panel submitted brief update of its 2024 special recommendations for HIV prevention to the Journal of the American Medical Association, which was published on June 27, 2025.
The updated recommendations can be found through the button below.
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel
Sax PE, Thompson MA, Saag MS, et al. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel. JAMA. 2024 Mar 26;331(12):1060-1061.doi: 10.1001/jama.2024.2985.